Search - tctmd.com

Displaying 121 - 132 of 132

Sort: Relevancy | Date

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

May 28, 2015

News Industry News

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

August 25, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

Video

» Interview

ACC 2022: PACMAN AMI - Effects Of Alirocumab On Coronary Atherosclerosis Assessed By Serial Multimodality Intracoronary Imaging In Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial

April 12, 2022

Advertisement

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

ACC 2022: PACMAN AMI - Effects Of Alirocumab On Coronary Atherosclerosis Assessed By Serial Multimodality Intracoronary Imaging In Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content